维康药业(300878) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥183,784,056.82, representing a 38.96% increase compared to ¥132,259,899.28 in the same period last year[4] - The net profit attributable to shareholders was ¥22,919,976.17, up 13.06% from ¥20,272,669.37 year-on-year[4] - Basic and diluted earnings per share increased by 12.00%, from ¥0.25 to ¥0.28[4] - The net profit for the first quarter of 2022 was CNY 23,128,425.85, an increase of 13.6% compared to CNY 20,371,610.56 in the same period last year[20] - The total profit for the first quarter was CNY 26,301,735.68, up from CNY 23,793,837.35, reflecting a growth of 10.6% year-over-year[20] - The operating profit increased to CNY 26,209,232.01 from CNY 23,685,671.98, marking a rise of 10.6%[20] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching -¥7,753,792.32, an 82.77% increase from -¥45,004,162.70 in the previous year[4] - Cash flow from operating activities showed a net outflow of CNY 7,753,792.32, an improvement from a net outflow of CNY 45,004,162.70 in the previous year[23] - Cash and cash equivalents at the end of the period were CNY 193,666,223.27, down from CNY 484,957,165.65 at the end of the previous year[24] - The company reported cash inflows from operating activities totaling CNY 162,034,979.37, compared to CNY 137,497,389.46 in the same period last year[23] - Total cash outflows from operating activities were CNY 169,788,771.69, a decrease from CNY 182,501,552.16 year-over-year[23] - Investment activities resulted in a net cash outflow of CNY 77,998,619.91, compared to CNY 49,228,549.30 in the previous year[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,698,866,952.67, a slight increase of 0.33% from ¥1,693,307,837.66 at the end of the previous year[4] - The company's cash and cash equivalents at the end of Q1 2022 were CNY 193,666,223.27, down from CNY 280,795,523.15 at the beginning of the year[16] - Accounts receivable increased to CNY 425,360,607.31 from CNY 373,660,578.13, indicating a rise of 13.8%[16] - Total liabilities decreased to CNY 275,458,017.59 from CNY 284,283,154.00, a reduction of 3.0%[17] - The company's retained earnings increased to CNY 535,619,956.63 from CNY 512,699,980.46, reflecting a growth of 4.5%[18] - The total equity attributable to shareholders rose to CNY 1,420,231,036.79 from CNY 1,397,311,060.62, an increase of 1.6%[18] Research and Development - The company reported a significant increase in R&D expenses, which rose by 90.83% to ¥7,808,286.33, reflecting increased investment in outsourced R&D projects[10] - Research and development expenses for Q1 2022 amounted to CNY 7,808,286.33, representing a 91.5% increase from CNY 4,091,733.61 in Q1 2021[19] Operating Costs - The company’s gross profit margin was impacted by a 97.42% increase in operating costs, which reached ¥88,408,553.56 due to rising raw material prices[10] - The total operating costs for Q1 2022 were CNY 162,915,922.80, up 51.7% from CNY 107,306,551.41 in Q1 2021[19] - The gross profit margin for Q1 2022 was approximately 11.4%, down from the previous year's margin due to increased costs[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,705, with the largest shareholder holding 60.89% of the shares[12] Government Support - The company received government subsidies amounting to ¥753,142.87, contributing to a 64.99% increase in other income to ¥926,038.72[10] Audit Information - The company did not conduct an audit for the first quarter report[25]